EGFR and non-small cell lung carcinoma: A clinical Phase II trial of pembrolizumab in TKI-naïve EGFR-mutant NSCLC patients with positive PD-L1 showed no response.[9] In addition, a pooled analysis of CheckMate 057, KEYNOTE-010, POPULAR, and OAK clinical trials revealed that ICI monotherapy provided no benefits over docetaxel as second-line treatment for EGFR-mutant NSCLC patients with failed EGFR-TKI therapy.[7] Moreover, data from the ImmunoTarget trial showed that the ORR and PFS of EGFR-mutant NSCLC patients treated with ICI monotherapy at any line of treatment were 12% and 2.1 m, respectively.[8]